

Product Name	: Crizotinib hydrochloride
Synonyms	: PF-02341066 hydrochloride; PF-2341066 hydrochloride
Cat No.	: M11726
CAS Number	: 1415560-69-8
Molecular Formula	: C ₂₁ H ₂₃ Cl ₃ FN ₅ O
Formula Weight	: 486.80
Chemical Name	: 2-Pyridinamine, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidyl)-1H-pyrazol-4-yl]-, hydrochloride (1:1)
Description	Crizotinib (PF-02341066; PF-2341066) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of c-Met catalytic activity with K_i of 4 nM; displays >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ~40- to 60-fold selective for Tie2, TrkA, and TrkB; also inhibits ALK (IC₅₀=24 nM), potently inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC₅₀=5-20 nM); shows antitumor efficacy in tumor models at well-tolerated doses in vivo. Lung Cancer Approved
Pathway	: Angiogenesis
Target	: ALK
Receptor	: ALK
Solubility	: DMSO: ≥ 4.6 mg/mL
SMILES	: <chem>CC(C1=C(C=CC(=C1Cl)F)Cl)OC2=C(N=CC(=C2)C3=CN(N=C3)C4CCNCC4)N.Cl</chem>
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Zou HY, et al. Cancer Res. 2007 May 1;67(9):4408-17. | 2. Christensen JG, et al. Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22. | 3. Knowles LM, et al. Clin Cancer Res. 2009 Jun 1;15(11):3740-50.